JasLYJ personal page - To The Moon

JasLYJ

No personal profile

3Follow

0Followers

0Topic

0Badge

2021-06-12

Hmmm…

Inflation is undergoing a ‘structural shift’ and these markets will benefit, strategist says

2021-06-12

Interesting

Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3571433323459611","uuid":"3571433323459611","gmtCreate":1608339866237,"gmtModify":1608339866237,"name":"JasLYJ","pinyin":"jaslyj","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":188228812,"gmtCreate":1623450565636,"gmtModify":1704203856495,"author":{"id":"3571433323459611","authorId":"3571433323459611","name":"JasLYJ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571433323459611","idStr":"3571433323459611"},"themes":[],"htmlText":"Hmmm…","listText":"Hmmm…","text":"Hmmm…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188228812","repostId":"1196090491","repostType":4,"repost":{"id":"1196090491","kind":"news","pubTimestamp":1623418568,"share":"https://ttm.financial/m/news/1196090491?lang=&edition=fundamental","pubTime":"2021-06-11 21:36","market":"us","language":"en","title":"Inflation is undergoing a ‘structural shift’ and these markets will benefit, strategist says","url":"https://stock-news.laohu8.com/highlight/detail?id=1196090491","media":"cnbc","summary":"KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May ","content":"<div>\n<p>KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May from the previous year, its sharpest increase since 2008.\nLivermore Partners has noted that wages ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inflation is undergoing a ‘structural shift’ and these markets will benefit, strategist says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflation is undergoing a ‘structural shift’ and these markets will benefit, strategist says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May from the previous year, its sharpest increase since 2008.\nLivermore Partners has noted that wages ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"source_url":"https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1196090491","content_text":"KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May from the previous year, its sharpest increase since 2008.\nLivermore Partners has noted that wages are not rising as much as would normally be expected alongside GDP growth rates upward of 6%. Real average hourly earnings, which account for inflation, were down 2.8% in May from the previous year.\n\nEuropean stocks are set to outperform the U.S. as inflation sticks around and commodities begin a new “supercycle,” according to Livermore Partners Chief Investment Officer David Neuhauser.\nTheU.S. consumer price index on Thursday showed a 5% jump in headline inflationin May from the previous year, its sharpest increase since 2008. Core inflation, which excludes volatile food and energy prices, also notched a 28-year high of 3.8%.\nWhilemarkets have broadly dismissedthe current red-hot inflation figures as transitory and fueled by short-term anomalous factors, Neuhauser argued that a more fundamental \"structural shift\" was taking place.\nLivermore Partners has noted that wages are not rising as much as would normally be expected alongside GDP growth rates upward of 6%. Real average hourly earnings in the U.S., which account for inflation, were down 2.8% in May from the previous year, according to theBureau of Labor Statistics.\n\"As you are seeing prices for automobiles, as prices for houses, as prices for food and energy go up, even though it looks like the economies are starting to boom, the real issue is you're not seeing wages grow as fast,\" Neuhauser told CNBC's \"Squawk Box Europe\" Friday.\n\"Thus ultimately that is going to start to pinch the consumer and as you know, the consumer is 70%-plus of the economy.\"\nIf inflation is indeed here to stay, as Livermore Partners anticipates, Neuhauser suggested this will cause troubles down the line and will cause the Federal Reserve to apply the brakes to its accommodative monetary policy.\nWage growth sluggish\nNeuhauser pointed to McDonald's and Chipotle as examples of companies that have begun to incur substantial and rising input costs while struggling to attract workers in the wake of the pandemic, leading them to offer bonuses and focus on wage growth.\n\"That is ultimately going to increase the price of their goods and services which will of course increase the prices to consumers,\" he added.\nThis could cause problems if these trends combine with the potential tapering of the Fed's unprecedented bond-buying program, Neuhauser suggested.\n“That is going to have the potential at least to start to rerate markets, which look extremely frothy. Ultimately, that is what you have to focus on as an investor,” he said.\n“You have to look at the numbers and you can push them off to the side, but you can’t do that if you start to see more consistent hotter numbers running forward.”\nCommodities ‘supercycle’\nNeuhauser’s fund is now largely focused on commodities, banks and industrials, as he believes commodities are in the start of a new “supercycle” — a decades-long period in which commodity prices remain above long-term trends.\n“We have seen (fewer) mines being built, we have seen oil and gas see capex (capital expenditure) being pulled away as banks aren’t lending anymore, you are seeing ESG initiatives make front and center stage when it comes to board meetings,” he said.\n“I think there has been this structural shift where you have not seen capital, capital has been starved to the complex and ultimately you have a dollar that is looking to potentially fall apart.”\nThis shift means commodities are the place to be for investors over the next three to five years, he argued.\n“We are playing that in terms of some of the smaller cap free cash flow or cash flow businesses out there,” he said.\n“A lot of it is in Europe and a lot of it is international, so I think Europe is going to outperform the U.S. as we go forward and that is where most of our capital is actually at Livermore, in a lot of these European stocks tied to mining.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188228057,"gmtCreate":1623450525079,"gmtModify":1704203856007,"author":{"id":"3571433323459611","authorId":"3571433323459611","name":"JasLYJ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3571433323459611","idStr":"3571433323459611"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188228057","repostId":"2142270837","repostType":4,"repost":{"id":"2142270837","kind":"highlight","pubTimestamp":1623424800,"share":"https://ttm.financial/m/news/2142270837?lang=&edition=fundamental","pubTime":"2021-06-11 23:20","market":"us","language":"en","title":"Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2142270837","media":"Motley Fool","summary":"It has a key advantage that should make a huge difference over the next 10 or more years.","content":"<p>You won't find hotter stars in the investing universe so far this year than&nbsp;<b>AMC Entertainment</b> (NYSE:AMC) and <b>Dogecoin</b> (CRYPTO:DOGE). Retail investors have jumped aboard their bandwagons in force. AMC's shares have vaulted more than 2,300% higher year to date, while the price of Dogecoin has skyrocketed over 5,600%.</p>\n<p>The big question for AMC and Dogecoin is whether or not their momentum is sustainable. There's considerable disagreement about the right answer to that question.</p>\n<p>Probably the better question to ask, though, is whether or not there are other investment alternatives that provide better risk-reward propositions over the next 10 years or more. My view is that the answer to this question is a resounding \"yes.\"</p>\n<p>Move over AMC and Dogecoin: Here's a stock that could be a bigger long-term winner.</p>\n<p><img src=\"https://static.tigerbbs.com/60aa704652c60d9c305da0999c714b57\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>A big advantage for a big biotech</h2>\n<p>The stock I have in mind is none other than&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX). Granted, Vertex hasn't delivered anywhere close to the kinds of returns that AMC and Dogecoin have in recent months. It even just reported a setback for <a href=\"https://laohu8.com/S/AONE\">one</a> of its pipeline candidates. However, this big biotech holds an advantage over both of them that should make a huge difference over the long run: Vertex enjoys a monopoly in its core market.</p>\n<p>There are currently four approved drugs in the U.S. and Europe that treat the underlying cause of rare genetic disease cystic fibrosis (CF), and Vertex markets all of them. Its newest CF drug, Trikafta/Kaftrio, is its biggest winner yet. The drug is just beginning to pick up momentum in Europe.</p>\n<p>What about potential rivals? <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other companies have clinical-stage candidates that target the underlying cause of CF. However, those experimental drugs are only in phase 2 testing, and there's no guarantee the candidates will be more effective than Vertex's products that are already on the market. Vertex seems likely to dominate the CF market, at least through the next decade.</p>\n<p>Let's compare Vertex's monopoly to the competitive dynamics for AMC and Dogecoin. AMC isn't the only theater chain. Its top rivals include <b>Cineplex</b>, <b>Cinemark</b>, <b>Marcus</b>, and Regal Entertainment. Streaming services that allow people to watch new movies at home are also a competitive threat to AMC.</p>\n<p>Dogecoin isn't the only cryptocurrency vying for investors' favor, either. There are other cryptocurrencies that seem even more likely to succeed over the next several years than Dogecoin.</p>\n<p>The bottom line is that Vertex has a moat, while AMC and Dogecoin don't. Over the long run, moats matter.</p>\n<h2>Looking to the future</h2>\n<p>Dogecoin likely has a hit-or-miss future. It either will become a top cryptocurrency that enjoys enduring use or it will fade away.</p>\n<p>On the other hand, AMC will probably experience a solid rebound as life returns to normal with fears about the COVID-19 pandemic waning. That should boost the company's sales this year and into 2022. But how long can AMC's growth story last? Movie-theater attendance was declining somewhat even before the pandemic. It won't be surprising to see that trend resume after an initial resurgence.</p>\n<p>Meanwhile, Vertex continues to focus on treating the remaining 10% of CF patients that its current drugs can't help. The company is also developing experimental therapies for other rare diseases, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, beta-thalassemia, Duchenne muscular dystrophy, and sickle cell disease.</p>\n<p>Vertex isn't limiting itself to just rare diseases, though. It's testing an experimental drug for the treatment of acute pain following certain types of surgeries in phase 2 clinical trials. The biotech is evaluating a gene therapy in a phase 1/2 study that holds the potential to essentially cure type 1 diabetes</p>\n<p>The important thing to note is that Vertex doesn't need all of these programs to be successful. If only <a href=\"https://laohu8.com/S/AONE.U\">one</a> or two of them pan out, this biotech stock should deliver tremendous returns.</p>\n<h2>Beyond the hype</h2>\n<p>I think it's quite possible that AMC and/or Dogecoin will outperform Vertex over the short term. If you're a short-term trader looking to capture quick profits, that's great. However, my focus from the beginning has been on the long term.</p>\n<p>Sooner or later, the hype for AMC and Dogecoin will die down. What happens then? Short-term traders will turn to another stock or cryptocurrency to ride.</p>\n<p>Vertex, though, is working every single day to treat and even cure diseases that cause suffering for many people around the world. Its CF franchise is generating billions of dollars in sales every year, and the company is using its growing cash stockpile to fund further development and make more deals to bolster its pipeline.</p>\n<p>My view is that these continuous efforts will make Vertex a bigger winner than either AMC or Dogecoin over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMove Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/11/move-over-amc-and-dogecoin-this-stock-could-be-a-m/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You won't find hotter stars in the investing universe so far this year than AMC Entertainment (NYSE:AMC) and Dogecoin (CRYPTO:DOGE). Retail investors have jumped aboard their bandwagons in force. AMC'...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/11/move-over-amc-and-dogecoin-this-stock-could-be-a-m/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VERX":"Vertex, Inc."},"source_url":"https://www.fool.com/investing/2021/06/11/move-over-amc-and-dogecoin-this-stock-could-be-a-m/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142270837","content_text":"You won't find hotter stars in the investing universe so far this year than AMC Entertainment (NYSE:AMC) and Dogecoin (CRYPTO:DOGE). Retail investors have jumped aboard their bandwagons in force. AMC's shares have vaulted more than 2,300% higher year to date, while the price of Dogecoin has skyrocketed over 5,600%.\nThe big question for AMC and Dogecoin is whether or not their momentum is sustainable. There's considerable disagreement about the right answer to that question.\nProbably the better question to ask, though, is whether or not there are other investment alternatives that provide better risk-reward propositions over the next 10 years or more. My view is that the answer to this question is a resounding \"yes.\"\nMove over AMC and Dogecoin: Here's a stock that could be a bigger long-term winner.\n\nImage source: Getty Images.\nA big advantage for a big biotech\nThe stock I have in mind is none other than Vertex Pharmaceuticals (NASDAQ:VRTX). Granted, Vertex hasn't delivered anywhere close to the kinds of returns that AMC and Dogecoin have in recent months. It even just reported a setback for one of its pipeline candidates. However, this big biotech holds an advantage over both of them that should make a huge difference over the long run: Vertex enjoys a monopoly in its core market.\nThere are currently four approved drugs in the U.S. and Europe that treat the underlying cause of rare genetic disease cystic fibrosis (CF), and Vertex markets all of them. Its newest CF drug, Trikafta/Kaftrio, is its biggest winner yet. The drug is just beginning to pick up momentum in Europe.\nWhat about potential rivals? Two other companies have clinical-stage candidates that target the underlying cause of CF. However, those experimental drugs are only in phase 2 testing, and there's no guarantee the candidates will be more effective than Vertex's products that are already on the market. Vertex seems likely to dominate the CF market, at least through the next decade.\nLet's compare Vertex's monopoly to the competitive dynamics for AMC and Dogecoin. AMC isn't the only theater chain. Its top rivals include Cineplex, Cinemark, Marcus, and Regal Entertainment. Streaming services that allow people to watch new movies at home are also a competitive threat to AMC.\nDogecoin isn't the only cryptocurrency vying for investors' favor, either. There are other cryptocurrencies that seem even more likely to succeed over the next several years than Dogecoin.\nThe bottom line is that Vertex has a moat, while AMC and Dogecoin don't. Over the long run, moats matter.\nLooking to the future\nDogecoin likely has a hit-or-miss future. It either will become a top cryptocurrency that enjoys enduring use or it will fade away.\nOn the other hand, AMC will probably experience a solid rebound as life returns to normal with fears about the COVID-19 pandemic waning. That should boost the company's sales this year and into 2022. But how long can AMC's growth story last? Movie-theater attendance was declining somewhat even before the pandemic. It won't be surprising to see that trend resume after an initial resurgence.\nMeanwhile, Vertex continues to focus on treating the remaining 10% of CF patients that its current drugs can't help. The company is also developing experimental therapies for other rare diseases, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, beta-thalassemia, Duchenne muscular dystrophy, and sickle cell disease.\nVertex isn't limiting itself to just rare diseases, though. It's testing an experimental drug for the treatment of acute pain following certain types of surgeries in phase 2 clinical trials. The biotech is evaluating a gene therapy in a phase 1/2 study that holds the potential to essentially cure type 1 diabetes\nThe important thing to note is that Vertex doesn't need all of these programs to be successful. If only one or two of them pan out, this biotech stock should deliver tremendous returns.\nBeyond the hype\nI think it's quite possible that AMC and/or Dogecoin will outperform Vertex over the short term. If you're a short-term trader looking to capture quick profits, that's great. However, my focus from the beginning has been on the long term.\nSooner or later, the hype for AMC and Dogecoin will die down. What happens then? Short-term traders will turn to another stock or cryptocurrency to ride.\nVertex, though, is working every single day to treat and even cure diseases that cause suffering for many people around the world. Its CF franchise is generating billions of dollars in sales every year, and the company is using its growing cash stockpile to fund further development and make more deals to bolster its pipeline.\nMy view is that these continuous efforts will make Vertex a bigger winner than either AMC or Dogecoin over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":188228812,"gmtCreate":1623450565636,"gmtModify":1704203856495,"author":{"id":"3571433323459611","authorId":"3571433323459611","name":"JasLYJ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571433323459611","authorIdStr":"3571433323459611"},"themes":[],"htmlText":"Hmmm…","listText":"Hmmm…","text":"Hmmm…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188228812","repostId":"1196090491","repostType":4,"repost":{"id":"1196090491","kind":"news","pubTimestamp":1623418568,"share":"https://ttm.financial/m/news/1196090491?lang=&edition=fundamental","pubTime":"2021-06-11 21:36","market":"us","language":"en","title":"Inflation is undergoing a ‘structural shift’ and these markets will benefit, strategist says","url":"https://stock-news.laohu8.com/highlight/detail?id=1196090491","media":"cnbc","summary":"KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May ","content":"<div>\n<p>KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May from the previous year, its sharpest increase since 2008.\nLivermore Partners has noted that wages ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inflation is undergoing a ‘structural shift’ and these markets will benefit, strategist says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflation is undergoing a ‘structural shift’ and these markets will benefit, strategist says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 21:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May from the previous year, its sharpest increase since 2008.\nLivermore Partners has noted that wages ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF"},"source_url":"https://www.cnbc.com/2021/06/11/strategist-inflation-is-in-a-structural-shift-and-these-markets-will-benefit.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1196090491","content_text":"KEY POINTS\n\nThe U.S. consumer price index on Thursday showed a 5% jump in headline inflation in May from the previous year, its sharpest increase since 2008.\nLivermore Partners has noted that wages are not rising as much as would normally be expected alongside GDP growth rates upward of 6%. Real average hourly earnings, which account for inflation, were down 2.8% in May from the previous year.\n\nEuropean stocks are set to outperform the U.S. as inflation sticks around and commodities begin a new “supercycle,” according to Livermore Partners Chief Investment Officer David Neuhauser.\nTheU.S. consumer price index on Thursday showed a 5% jump in headline inflationin May from the previous year, its sharpest increase since 2008. Core inflation, which excludes volatile food and energy prices, also notched a 28-year high of 3.8%.\nWhilemarkets have broadly dismissedthe current red-hot inflation figures as transitory and fueled by short-term anomalous factors, Neuhauser argued that a more fundamental \"structural shift\" was taking place.\nLivermore Partners has noted that wages are not rising as much as would normally be expected alongside GDP growth rates upward of 6%. Real average hourly earnings in the U.S., which account for inflation, were down 2.8% in May from the previous year, according to theBureau of Labor Statistics.\n\"As you are seeing prices for automobiles, as prices for houses, as prices for food and energy go up, even though it looks like the economies are starting to boom, the real issue is you're not seeing wages grow as fast,\" Neuhauser told CNBC's \"Squawk Box Europe\" Friday.\n\"Thus ultimately that is going to start to pinch the consumer and as you know, the consumer is 70%-plus of the economy.\"\nIf inflation is indeed here to stay, as Livermore Partners anticipates, Neuhauser suggested this will cause troubles down the line and will cause the Federal Reserve to apply the brakes to its accommodative monetary policy.\nWage growth sluggish\nNeuhauser pointed to McDonald's and Chipotle as examples of companies that have begun to incur substantial and rising input costs while struggling to attract workers in the wake of the pandemic, leading them to offer bonuses and focus on wage growth.\n\"That is ultimately going to increase the price of their goods and services which will of course increase the prices to consumers,\" he added.\nThis could cause problems if these trends combine with the potential tapering of the Fed's unprecedented bond-buying program, Neuhauser suggested.\n“That is going to have the potential at least to start to rerate markets, which look extremely frothy. Ultimately, that is what you have to focus on as an investor,” he said.\n“You have to look at the numbers and you can push them off to the side, but you can’t do that if you start to see more consistent hotter numbers running forward.”\nCommodities ‘supercycle’\nNeuhauser’s fund is now largely focused on commodities, banks and industrials, as he believes commodities are in the start of a new “supercycle” — a decades-long period in which commodity prices remain above long-term trends.\n“We have seen (fewer) mines being built, we have seen oil and gas see capex (capital expenditure) being pulled away as banks aren’t lending anymore, you are seeing ESG initiatives make front and center stage when it comes to board meetings,” he said.\n“I think there has been this structural shift where you have not seen capital, capital has been starved to the complex and ultimately you have a dollar that is looking to potentially fall apart.”\nThis shift means commodities are the place to be for investors over the next three to five years, he argued.\n“We are playing that in terms of some of the smaller cap free cash flow or cash flow businesses out there,” he said.\n“A lot of it is in Europe and a lot of it is international, so I think Europe is going to outperform the U.S. as we go forward and that is where most of our capital is actually at Livermore, in a lot of these European stocks tied to mining.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":287,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":188228057,"gmtCreate":1623450525079,"gmtModify":1704203856007,"author":{"id":"3571433323459611","authorId":"3571433323459611","name":"JasLYJ","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571433323459611","authorIdStr":"3571433323459611"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/188228057","repostId":"2142270837","repostType":4,"repost":{"id":"2142270837","kind":"highlight","pubTimestamp":1623424800,"share":"https://ttm.financial/m/news/2142270837?lang=&edition=fundamental","pubTime":"2021-06-11 23:20","market":"us","language":"en","title":"Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner","url":"https://stock-news.laohu8.com/highlight/detail?id=2142270837","media":"Motley Fool","summary":"It has a key advantage that should make a huge difference over the next 10 or more years.","content":"<p>You won't find hotter stars in the investing universe so far this year than&nbsp;<b>AMC Entertainment</b> (NYSE:AMC) and <b>Dogecoin</b> (CRYPTO:DOGE). Retail investors have jumped aboard their bandwagons in force. AMC's shares have vaulted more than 2,300% higher year to date, while the price of Dogecoin has skyrocketed over 5,600%.</p>\n<p>The big question for AMC and Dogecoin is whether or not their momentum is sustainable. There's considerable disagreement about the right answer to that question.</p>\n<p>Probably the better question to ask, though, is whether or not there are other investment alternatives that provide better risk-reward propositions over the next 10 years or more. My view is that the answer to this question is a resounding \"yes.\"</p>\n<p>Move over AMC and Dogecoin: Here's a stock that could be a bigger long-term winner.</p>\n<p><img src=\"https://static.tigerbbs.com/60aa704652c60d9c305da0999c714b57\" tg-width=\"700\" tg-height=\"525\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>A big advantage for a big biotech</h2>\n<p>The stock I have in mind is none other than&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX). Granted, Vertex hasn't delivered anywhere close to the kinds of returns that AMC and Dogecoin have in recent months. It even just reported a setback for <a href=\"https://laohu8.com/S/AONE\">one</a> of its pipeline candidates. However, this big biotech holds an advantage over both of them that should make a huge difference over the long run: Vertex enjoys a monopoly in its core market.</p>\n<p>There are currently four approved drugs in the U.S. and Europe that treat the underlying cause of rare genetic disease cystic fibrosis (CF), and Vertex markets all of them. Its newest CF drug, Trikafta/Kaftrio, is its biggest winner yet. The drug is just beginning to pick up momentum in Europe.</p>\n<p>What about potential rivals? <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> other companies have clinical-stage candidates that target the underlying cause of CF. However, those experimental drugs are only in phase 2 testing, and there's no guarantee the candidates will be more effective than Vertex's products that are already on the market. Vertex seems likely to dominate the CF market, at least through the next decade.</p>\n<p>Let's compare Vertex's monopoly to the competitive dynamics for AMC and Dogecoin. AMC isn't the only theater chain. Its top rivals include <b>Cineplex</b>, <b>Cinemark</b>, <b>Marcus</b>, and Regal Entertainment. Streaming services that allow people to watch new movies at home are also a competitive threat to AMC.</p>\n<p>Dogecoin isn't the only cryptocurrency vying for investors' favor, either. There are other cryptocurrencies that seem even more likely to succeed over the next several years than Dogecoin.</p>\n<p>The bottom line is that Vertex has a moat, while AMC and Dogecoin don't. Over the long run, moats matter.</p>\n<h2>Looking to the future</h2>\n<p>Dogecoin likely has a hit-or-miss future. It either will become a top cryptocurrency that enjoys enduring use or it will fade away.</p>\n<p>On the other hand, AMC will probably experience a solid rebound as life returns to normal with fears about the COVID-19 pandemic waning. That should boost the company's sales this year and into 2022. But how long can AMC's growth story last? Movie-theater attendance was declining somewhat even before the pandemic. It won't be surprising to see that trend resume after an initial resurgence.</p>\n<p>Meanwhile, Vertex continues to focus on treating the remaining 10% of CF patients that its current drugs can't help. The company is also developing experimental therapies for other rare diseases, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, beta-thalassemia, Duchenne muscular dystrophy, and sickle cell disease.</p>\n<p>Vertex isn't limiting itself to just rare diseases, though. It's testing an experimental drug for the treatment of acute pain following certain types of surgeries in phase 2 clinical trials. The biotech is evaluating a gene therapy in a phase 1/2 study that holds the potential to essentially cure type 1 diabetes</p>\n<p>The important thing to note is that Vertex doesn't need all of these programs to be successful. If only <a href=\"https://laohu8.com/S/AONE.U\">one</a> or two of them pan out, this biotech stock should deliver tremendous returns.</p>\n<h2>Beyond the hype</h2>\n<p>I think it's quite possible that AMC and/or Dogecoin will outperform Vertex over the short term. If you're a short-term trader looking to capture quick profits, that's great. However, my focus from the beginning has been on the long term.</p>\n<p>Sooner or later, the hype for AMC and Dogecoin will die down. What happens then? Short-term traders will turn to another stock or cryptocurrency to ride.</p>\n<p>Vertex, though, is working every single day to treat and even cure diseases that cause suffering for many people around the world. Its CF franchise is generating billions of dollars in sales every year, and the company is using its growing cash stockpile to fund further development and make more deals to bolster its pipeline.</p>\n<p>My view is that these continuous efforts will make Vertex a bigger winner than either AMC or Dogecoin over the long term.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMove Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-11 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/11/move-over-amc-and-dogecoin-this-stock-could-be-a-m/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You won't find hotter stars in the investing universe so far this year than AMC Entertainment (NYSE:AMC) and Dogecoin (CRYPTO:DOGE). Retail investors have jumped aboard their bandwagons in force. AMC'...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/11/move-over-amc-and-dogecoin-this-stock-could-be-a-m/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VERX":"Vertex, Inc."},"source_url":"https://www.fool.com/investing/2021/06/11/move-over-amc-and-dogecoin-this-stock-could-be-a-m/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2142270837","content_text":"You won't find hotter stars in the investing universe so far this year than AMC Entertainment (NYSE:AMC) and Dogecoin (CRYPTO:DOGE). Retail investors have jumped aboard their bandwagons in force. AMC's shares have vaulted more than 2,300% higher year to date, while the price of Dogecoin has skyrocketed over 5,600%.\nThe big question for AMC and Dogecoin is whether or not their momentum is sustainable. There's considerable disagreement about the right answer to that question.\nProbably the better question to ask, though, is whether or not there are other investment alternatives that provide better risk-reward propositions over the next 10 years or more. My view is that the answer to this question is a resounding \"yes.\"\nMove over AMC and Dogecoin: Here's a stock that could be a bigger long-term winner.\n\nImage source: Getty Images.\nA big advantage for a big biotech\nThe stock I have in mind is none other than Vertex Pharmaceuticals (NASDAQ:VRTX). Granted, Vertex hasn't delivered anywhere close to the kinds of returns that AMC and Dogecoin have in recent months. It even just reported a setback for one of its pipeline candidates. However, this big biotech holds an advantage over both of them that should make a huge difference over the long run: Vertex enjoys a monopoly in its core market.\nThere are currently four approved drugs in the U.S. and Europe that treat the underlying cause of rare genetic disease cystic fibrosis (CF), and Vertex markets all of them. Its newest CF drug, Trikafta/Kaftrio, is its biggest winner yet. The drug is just beginning to pick up momentum in Europe.\nWhat about potential rivals? Two other companies have clinical-stage candidates that target the underlying cause of CF. However, those experimental drugs are only in phase 2 testing, and there's no guarantee the candidates will be more effective than Vertex's products that are already on the market. Vertex seems likely to dominate the CF market, at least through the next decade.\nLet's compare Vertex's monopoly to the competitive dynamics for AMC and Dogecoin. AMC isn't the only theater chain. Its top rivals include Cineplex, Cinemark, Marcus, and Regal Entertainment. Streaming services that allow people to watch new movies at home are also a competitive threat to AMC.\nDogecoin isn't the only cryptocurrency vying for investors' favor, either. There are other cryptocurrencies that seem even more likely to succeed over the next several years than Dogecoin.\nThe bottom line is that Vertex has a moat, while AMC and Dogecoin don't. Over the long run, moats matter.\nLooking to the future\nDogecoin likely has a hit-or-miss future. It either will become a top cryptocurrency that enjoys enduring use or it will fade away.\nOn the other hand, AMC will probably experience a solid rebound as life returns to normal with fears about the COVID-19 pandemic waning. That should boost the company's sales this year and into 2022. But how long can AMC's growth story last? Movie-theater attendance was declining somewhat even before the pandemic. It won't be surprising to see that trend resume after an initial resurgence.\nMeanwhile, Vertex continues to focus on treating the remaining 10% of CF patients that its current drugs can't help. The company is also developing experimental therapies for other rare diseases, including alpha-1 antitrypsin deficiency, APOL1-mediated kidney diseases, beta-thalassemia, Duchenne muscular dystrophy, and sickle cell disease.\nVertex isn't limiting itself to just rare diseases, though. It's testing an experimental drug for the treatment of acute pain following certain types of surgeries in phase 2 clinical trials. The biotech is evaluating a gene therapy in a phase 1/2 study that holds the potential to essentially cure type 1 diabetes\nThe important thing to note is that Vertex doesn't need all of these programs to be successful. If only one or two of them pan out, this biotech stock should deliver tremendous returns.\nBeyond the hype\nI think it's quite possible that AMC and/or Dogecoin will outperform Vertex over the short term. If you're a short-term trader looking to capture quick profits, that's great. However, my focus from the beginning has been on the long term.\nSooner or later, the hype for AMC and Dogecoin will die down. What happens then? Short-term traders will turn to another stock or cryptocurrency to ride.\nVertex, though, is working every single day to treat and even cure diseases that cause suffering for many people around the world. Its CF franchise is generating billions of dollars in sales every year, and the company is using its growing cash stockpile to fund further development and make more deals to bolster its pipeline.\nMy view is that these continuous efforts will make Vertex a bigger winner than either AMC or Dogecoin over the long term.","news_type":1},"isVote":1,"tweetType":1,"viewCount":309,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}